A biologic agent known as tildrakizumab has demonstrated a positive outcome in two Phase III trials conducted by Harvard Medical School’s Beth Israel Deaconess Medical Centre (BIDMC) to treat patients with plaque psoriasis.

Tildrakizumab is based on the body’s natural molecules such as antibodies and targets a specific pathway.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The results showed that tildrakizumab is efficacious and well-tolerated in moderate-to-severe chronic plaque psoriasis patients.

The parallel, double-blind, randomised, controlled Phase III trials evaluated the ability of 100mg or 200mg of tildrakizumab to clear up and control the disease in more than 1,800 patients.

The reSURFACE 1 and reSURFACE 2 trials were performed at 250 sites in Austria, Australia, Belgium, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, the UK and the US.

See Also:

"The breakthrough here is that we have continued to refine our treatments to those that are likely to be most effective against psoriasis but less likely to affect other important pathways at the same time."

BIDMC Harvard Medical Faculty Physicians (HMFP) president and CEO Alexa Kimball said: “In these two trials, we tested whether this new, very targeted approach to a selected part of the inflammatory pathway would be effective in treating psoriasis, and it was, dramatically so.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The data showed that 65% of the patients in the trial with 30% of their body covered with psoriasis, experienced a complete skin clearance or had almost clear skin at the end of the treatment period.

The clearance represented a 75% improvement when compared to 10% by placebo, measured using the standard psoriasis area severity index (PASI).

Kimball further added: “The breakthrough here is that we have continued to refine our treatments to those that are likely to be most effective against psoriasis but less likely to affect other important pathways at the same time.”